Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind trial of oral micronized progesterone vs placebo for vasomotor symptoms in postmenopausal women
2016-004386-12Phase 3Completed
- Sponsor
- Besins Healthcare
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of progesterone in menopause and hot flash (3 arms), sponsored by Besins Healthcare. Primary endpoint: Change in daily frequency of moderate or severe vasomotor symptom episodes at 12 weeks. Started May 2017; status: completed.
02
Drugs
progesterone
03
Conditions
menopausehot flash
Beyond the preview
Go deeper on 2016-004386-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004386-12.